bildliche Darstellung

Ursachen, Symptome, Diagnose & Behandlung


Erfahren SIe hier mehr über die Behandlung von Rosacea - ob Rezept per Fragebogen oder Arztgespräch per Telefon oder Video.


  1. McAleer MA, Fitzpatrick P, Powell FC. Papulopustular rosacea: prevalence and relationship to photodamage. Journal of the American Academy of Dermatology. 2010;63(1):33-9.
  2. Elewski BE, Draelos Z, Dreno B, Jansen T, Layton A, Picardo M. Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. Journal of the European Academy of Dermatology and Venereology : JEADV. 2011;25(2):188-200.
  3. Aksoy B, Altaykan-Hapa A, Egemen D, Karagoz F, Atakan N. The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities. The British journal of dermatology. 2010;163(4):719-25.
  4. Mc Aleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia. 2009;144(6):663-71.
  5. Dahl MV. Pathogenesis of rosacea. Advances in dermatology. 2001;17:29-45.
  6. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. Journal of the American Academy of Dermatology. 2004;51(3):327-41; quiz 42-4.
  7. Wilkin J. A role for vascular pathogenic mechanisms in rosacea: implications for patient care. Cutis. 2008;82(2):100-2.
  8. Yamasaki K, Gallo RL. The molecular pathology of rosacea. Journal of dermatological science. 2009;55(2):77-81.
  9. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nature medicine. 2007;13(8):975-80.
  10. Abram K, Silm H, Maaroos HI, Oona M. Risk factors associated with rosacea. Journal of the European Academy of Dermatology and Venereology : JEADV. 2010;24(5):565-71.
  11. Schaller M, Almeida LM, Bewley A, Cribier B, Dlova NC, Kautz G, et al. Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. The British journal of dermatology. 2017;176(2):465-71.
  12. Odom R, Dahl M, Dover J, Draelos Z, Drake L, Macsai M, et al. Standard management options for rosacea, part 2: options according to subtype. Cutis. 2009;84(2):97-104.
  13. Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. The British journal of dermatology. 2012;166(3):633-41.
  14. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Advances in therapy. 2001;18(6):237-43.
  15. van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. The Cochrane database of systematic reviews. 2015(4):Cd003262.
  16. Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, et al. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. Journal of drugs in dermatology : JDD. 2014;13(11):1380-6.
  17. Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. Journal of drugs in dermatology : JDD. 2014;13(3):316-23.
  18. Goldberg DJ. Lasers and light sources for rosacea. Cutis. 2005;75(3 Suppl):22-6; discussion 33-6.
  19. Wilkin JK. Use of topical products for maintaining remission in rosacea. Archives of dermatology. 1999;135(1):79-80.